The FDA has issued an alert about a potentially high-risk issue involving Abiomed’s Automated Impella Controller, which is used with the company’s blood pump systems.
Abiomed, now part of Johnson & Johnson Medtech, notified customers June 23 with updated instructions for use and urgent recommendations, including having a backup AIC console on hand in the event of a device failure, according to a July 1 news release from the agency.
The FDA noted that the AIC may fail to detect a pump during console-to-console transfer or initial case startup without displaying a visual alarm. This could lead to inadequate hemodynamic support, posing critical risk for patients in cardiogenic shock.
The devicemaker recommends immediately switching back to a functioning console if the screen remains stuck after 20 seconds during a transfer or case start.
The issue has been linked to three patient deaths.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
